Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutrition 21 Diachrome, Zeramax Sales To Be Backed By Research Initiatives

This article was originally published in The Tan Sheet

Executive Summary

Nutrition 21 plans to support the broad launch of its Diachrome chromium picolinate/biotin blend with a relatively large-scale clinical study, according to President and CEO Gail Montgomery

You may also be interested in...



Nutrition 21

Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...

Nutrition 21

Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...

Nutrition 21

Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel